M24-147: A Phase 2, Randomized Open-Label Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC

The purpose of this study is to determine the optimal dose of livmoniplimab and to determine if livmoniplimab in combination with budigalimab is safe and effective at treating locally advanced or metastatic Child-Pugh A hepatocellular carcinoma (mHCC) patients who have progressed after an immune checkpoint inhibitor (CPI) containing regimen in first-line HCC.